Solid Dosage

Anti-virals

GEA supplies solutions for manufacturing inhalable and oral antiviral drugs ranging from blending, spray drying and particle engineering to continuous manufacturing.

Manufacturing Anti-virals

Antiviral medications help the body to fight off harmful viruses such as influenza, chickenpox and the human immunodeficiency virus (HIV), to name a few. The drugs can ease symptoms and shorten the length of a viral infection. Antivirals also lower the risk of getting or spreading viruses that cause herpes and HIV. One approved antiviral treats the coronavirus that causes COVID-19.

Antiviral drugs are also preventive. They can protect you from getting viral infections or spreading a virus to others. They come in many formats, including tablets, intravenous solutions, liquids and inhaled powders.

For inhalable versions, GEA understands that homogeneity and stability are key factors. Our dry powder blending, spray drying and particle engineering capabilities ensure that the production of free-flowing, aerodynamic particles at the correct size is achievable at the scale you need.

And, with the ongoing development of oral anti-viral medications, particularly as a result of the COVID-19, pandemic, there is increased interest in the use of continuous manufacturing to accelerate process design and product optimization.

For example, the compact and fully integrated ConsiGma®4.0 platform has been designed to transfer powder into coated tablets in a shorter time frame. Plus, by combining Quality by Design (QbD) principles with Design of Experiments (DoE), it enables operators to explore the design space in a quick and easy way and expedite time-to-market. 

Downloads

Insights da GEA

Human hands brought together to form a circle

In for the better: Community engagement at GEA

To support community engagement, GEA offers employees one day of paid time off per year.

How a digital rotary parlor supports sustainable dairy farming

How do you lead a dairy farm into the next generation while ensuring a sustainable future and animal welfare while managing increasing complexity? This is a question almost every dairy farmer around the world must consider. The...

GEA misison 30 logo

A strategy for the better: CEO interview on GEA's Mission 30

After reaching its Mission 26 targets two years early, GEA launches Mission 2030 strategy with focus on growth, value and making a positive impact.

Receba notícias da GEA

Mantenha-se atualizado com as inovações e histórias da GEA, se registrando para receber notícias sobre a GEA.

Entre em contato

Estamos aqui para ajudar! Com apenas poucos detalhes poderemos responder à sua pergunta.